DNA 마이크로어레이 시장 예측(-2030년) : 유형별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global DNA Microarray Market is accounted for $3.7 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 10.7% during the forecast period. A DNA microarray is a powerful tool used in molecular biology to simultaneously analyze the expression levels of thousands of genes in a single experiment. It consists of an arrayed series of microscopic spots containing DNA probes, each spot representing a specific gene or fragment of a gene. By hybridizing fluorescently labelled DNA or RNA samples onto these spots, scientists can detect and measure the expression levels of thousands of genes in a given sample, providing insights into gene function, regulation, and interactions within biological systems. This technology has been pivotal in fields like genomics, genetics, and biomedical research.

According to estimates by the Canadian Cancer Society, the country reported 233,900 new cancer cases with 85,100 deaths.

Market Dynamics:

Driver:

Advancements in genomics research

Genomics research within the DNA Microarray market has witnessed substantial advancements, revolutionizing personalized medicine and disease understanding. Innovations in microarray technology propel research in gene expression, mutation analysis, and genomic variations. Improved bioinformatics tools streamline data analysis, enabling comprehensive insights into complex biological systems. These advancements foster applications in clinical diagnostics, drug discovery, and biomarker identification, paving the way for precision medicine and targeted therapies.

Restraint:

Ethical and privacy concerns

DNA Microarrays pose ethical concerns due to potential misuse of genetic data, raising issues of privacy infringement, consent, and discrimination. The vast data collected can be exploited, compromising individuals' sensitive information without their informed consent. Additionally, concerns arise regarding the accuracy and interpretation of results, potentially impacting individuals' lives based on uncertain or misinterpreted genetic data. These are the factors restraining the growth of the segment.

Opportunity:

Rising demand for personalized medicine

The market is witnessing a surge in demand due to the growing interest in personalized medicine. This trend is fuelled by the technology's ability to analyze an individual's genetic makeup swiftly and accurately, enabling tailored treatment plans. As healthcare shifts toward precision medicine, these microarrays play a pivotal role by offering insights into genetic variations, aiding in targeted therapies, and enhancing patient outcomes. This rising demand underscores the pivotal role in advancing personalized healthcare solutions.

Threat:

High costs

The market has historically faced high costs due to intricate manufacturing processes, specialized equipment, and the need for precise quality control measures. These factors contribute to elevated expenses in raw materials, research, development, and production. Additionally, the complexity of the technology and the demand for accuracy and reliability further drives up costs, making microarrays a costly investment for research and diagnostic purposes.

Covid-19 Impact:

The COVID-19 pandemic triggered fluctuations in the DNA Microarray market. Initially, disruptions in supply chains and lab closures led to a slowdown. However, increased demand for diagnostics and research purposes, along with advancements in personalized medicine, boosted market growth. Rapid innovation and adaptation in technology for remote work and data analysis also influenced the market positively. Overall, the pandemic caused fluctuations but ultimately accelerated technological advancements and market expansion in applications.

The Pharmacogenomics segment is expected to be the largest during the forecast period

The pharmacogenomics segment is expected to be the largest during the forecast period. This segment utilizes DNA microarrays to identify genetic variations influencing drug metabolism, efficacy, and adverse reactions, guiding personalized treatment approaches. Its growth is driven by the demand for precision medicine, enabling tailored drug selection and dosing for better patient outcomes, making it a pivotal player in the healthcare industry's quest for personalized therapeutic interventions.

The diagnostic centers segment is expected to have the highest CAGR during the forecast period

The diagnostic centers segment is expected to have the highest CAGR during the forecast period. These centers employ microarrays to simultaneously examine numerous genes, identifying variations linked to illnesses. Advancements in microarray platforms enhance precision and throughput, fostering quicker diagnoses and personalized treatment strategies. This market segment thrives due to its pivotal role in decoding genetic information, driving innovation for targeted therapies and precise medical interventions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The region's market growth is propelled by rising investments in genomics, personalized medicine, and biotechnology. Factors such as increased adoption of advanced healthcare technologies, strategic collaborations, and a supportive regulatory environment contribute to the market's expansion, catering to diverse applications across research, diagnostics, and pharmaceutical industries.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region's market witnesses escalating demand for personalized medicine, genetic research, and diagnostics, fostering market expansion. Key players, strategic collaborations, and government support for genomics research contribute to the market's steady rise. Moreover, growing awareness and adoption of genomic technologies among healthcare professionals and researchers further fuel the market's evolution in the region.

Key players in the market

Some of the key players in DNA Microarray market include Applied Micro Arrays, Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Merck KGaA, Agilent Technologies, Inc., Bio-Rad Laboratories, PerkinElmer, Oxford Gene Technology (OGT), Arrayit Corporation, Roche NimbleGen, Savyon Diagnostics, WaferGen Biosystems, Novacyt Group and Enzo Biochem, Inc.

Key Developments:

In August 2022, Thermo Fisher Scientific launched a new chromosomal microarray, the Applied Biosystem CytoScan HD Accel array, to improve cytogenetic research lab productivity, efficiency, and profitability with two-day turnaround time. This strategy helped the company to expand their product portfolio.

In May 2022, Qatar Genome Program and Thermo Fisher Scientific announced a partnership to accelerate genomic research and clinical applications of predictive genomics in Qatar.

Types Covered:

• Oligonucleotide DNA Microarrays (oDNA)
• Complementary DNA Microarrays (cDNA)
• Other Types

Technologies Covered:

• Inkjet
• Microfluidics
• Hybridization
• Other Technologies

Applications Covered:

• Gene Expression Analysis
• Cancer Research
• Genotyping
• Genetics
• Drug Discovery
• Forensic Science
• Neuroscience
• Other Applications

End Users Covered:

• Contract Research Organizations (CROs)
• Biotechnology Companies
• Hospitals and Clinics
• Academic and Research Institutes
• Diagnostic Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global DNA Microarray Market, By Type

• 5.1 Introduction
• 5.2 Oligonucleotide DNA Microarrays (oDNA)
• 5.3 Complementary DNA Microarrays (cDNA)
• 5.4 Other Types

6 Global DNA Microarray Market, By Technology

• 6.1 Introduction
• 6.2 Inkjet
• 6.3 Microfluidics
• 6.4 Hybridization
• 6.5 Other Technologies

7 Global DNA Microarray Market, By Application

• 7.1 Introduction
• 7.2 Pharmacogenomics
• 7.3 Gene Expression Analysis
• 7.4 Cancer Research
• 7.5 Genotyping
• 7.6 Proteomics
• 7.7 Toxicogenomics
• 7.8 Genetics
• 7.9 Drug Discovery
• 7.10 Forensic Science
• 7.11 Neuroscience
• 7.12 Other Applications

8 Global DNA Microarray Market, By End User

• 8.1 Introduction
• 8.2 Contract Research Organizations (CROs)
• 8.3 Biotechnology Companies
• 8.4 Hospitals and Clinics
• 8.5 Academic and Research Institutes
• 8.6 Diagnostic Centers
• 8.7 Other End Users

9 Global DNA Microarray Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Applied Micro Arrays
• 11.2 Illumina, Inc.
• 11.3 QIAGEN
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Thermo Fisher Scientific, Inc.
• 11.6 PerkinElmer, Inc.
• 11.7 Merck KGaA
• 11.8 Agilent Technologies, Inc.
• 11.9 Bio-Rad Laboratories
• 11.10 PerkinElmer
• 11.11 Oxford Gene Technology (OGT)
• 11.12 Arrayit Corporation
• 11.11 Roche NimbleGen
• 11.14 Savyon Diagnostics
• 11.15 WaferGen Biosystems
• 11.16 Novacyt Group
• 11.17 Enzo Biochem, Inc.